Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-oncology Wen, P. Y., Weller, M., Lee, E. Q., Touat, M., Khasraw, M., Rahman, R., Platten, M., Lim, M., Winkler, F., Horbinski, C., Verhaak, R. G., Huang, R. Y., Ahluwalia, M. S., Albert, N. L., Tonn, J. C., Schiff, D., Barnholtz-Sloan, J. S., Ostrom, Q., Aldape, K. D., Batchelor, T. T., Bindra, R. S., Chiocca, E. A., Cloughesy, T. F., DeGroot, J. F., French, P., Galanis, E., Galldiks, N., Gilbert, M. R., Hegi, M. E., Lassman, A. B., Le Rhun, E., Mehta, M. P., Mellinghoff, I. K., Minniti, G., Roth, P., Sanson, M., Taphoorn, M. J., von Deimling, A., Weiss, T., Wick, W., Zadeh, G., Reardon, D. A., Chang, S. M., Short, S. C., van den Bent, M. J., Preusser, M. 2025

Abstract

Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled into clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics and antibody-drug conjugates will be reviewed, as well as the current challenges and future directions for research.

View details for DOI 10.1093/neuonc/noaf177

View details for PubMedID 40827022